HOME >> MEDICINE >> NEWS
DOE commits $27.5M for uranium contaminant transport field studies

RICHLAND, Wash. The Department of Energy recently granted Pacific Northwest National Laboratory $27.5 million dollars over 5 years to investigate the movement of contaminated groundwater at sites in Washington and Colorado. These two field research studies are funded by DOE's Office of Science and are intended to identify new approaches and strategies to help resolve questions about the movement of subsurface contaminants.

PNNL will lead the field studies at the Hanford Site in Richland, Wash., and at a uranium mill tailings site in Rifle, Colo.

The Hanford study involves characterization and instrumentation of field sites to investigate the groundwater and the vadose zone - or the subsurface soil and rock just above the groundwater - both of which are contaminated by uranium. The study area is adjacent to the Columbia River and located near the southern boundary of the Hanford Site, north of Richland.

PNNL Project Manager John Zachara says the field study at Hanford is perfectly suited for closely examining the processes controlling uranium migration in a complex subsurface environment. "It brings to bear the best science available, and will help us resolve questions about the movement of subsurface contaminants at Hanford and other DOE sites."

The five-year research project will help develop transport models that will be relevant and applicable to contaminant movement along the entire Columbia River corridor, according to Zachara. A team of scientists from PNNL and researchers from three other DOE laboratories, four universities and the U.S. Geological Survey are involved. DOE contractor Fluor Hanford is responsible for remediating the groundwater and deep vadose zone in this area.

The Hanford field study complements investments by the DOE Office of Environmental Management to investigate an innovative cleanup approach for the uranium. "It's a collaborative effort that benefits both endeavors," Zach
'"/>

Contact: Geoff Harvey
geoffrey.harvey@pnl.gov
509-372-6083
DOE/Pacific Northwest National Laboratory
16-Apr-2007


Page: 1 2 3

Related medicine news :

1. CNIC commits 5 million Euros to the Mount Sinai School of Medicine
2. Disposable sensor uses DNA to detect hazardous uranium ions
3. Novel Ames Lab composite may replace depleted uranium
4. Secondhand smoke in cars may lead to dangerous levels of contaminants for children
5. Increasing survival of organ transplant patients by reducing time interval for transported organs
6. Navigable nanotransport
7. Mechanism for neurodenegerative diseases linked to transport proteins
8. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
9. Electric fields have potential as a cancer treatment
10. Soldiers acquired drug-resistant infections in field hospitals
11. No increased risk of certain cancers from electromagnetic fields among energy workers

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: DOE commits for uranium contaminant transport field studies

(Date:5/24/2013)... HealthDay Reporter , , FRIDAY, May 24 (HealthDay News) -- ... But it was a physical challenge in her childhood ... sport. "I was an 11-year-old girl with my ... diagnosed by my orthopedic surgeon," said Lewis, who has ... and the American Academy of Orthopaedic Surgeons so she ...
(Date:5/24/2013)... Pomona, Calif. (PRWEB) May 24, 2013 ... has retained its status of “Full Accreditation” for the ... (AVMA) Council on Education (COE). , “This is a ... of our hard work and student outcomes,” said College ... want to express my appreciation to the faculty, staff, ...
(Date:5/24/2013)... KC and Monica Craichy, Founders of Living Fuel, Inc ... Kyle and Austin Craichy, will be kiteboarding with members of ... , KC Craichy said he is excited to be involved ... that virtually everyone who planned to be involved is going ... meet at Matheson Hammock Park and Beach in Miami at ...
(Date:5/24/2013)... The Mirena IUD lawyers at ... the FDA has received more than 59,229 complaints since 2004 ... intrauterine birth control device known as the Mirena IUD.* , ... by the women “included ‘expulsion,’ where the IUD came out ... according to an ABC News article. “Abdominal pain is also ...
(Date:5/24/2013)... 2013 E-Dentists.com has announced the launch ... JD Media Surge, a leading medical Internet marketing agency. ... analysis service will focus on providing dentists the help ... for their competitive keywords. The dental SEO analysis covers ... based on what their competitors are doing right. The ...
Breaking Medicine News(10 mins):Health News:Top-Ranked Golfer Beats Scoliosis 2Health News:Top-Ranked Golfer Beats Scoliosis 3Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3Health News:Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes 2Health News:Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge 2
(Date:5/24/2013)... , May 24, 2013 In accordance with Rule ... Rule 14e-1 of the United States Exchange Act, Echo Pharma ... offer for Elan Corporation (NYSE: ELN). Background ... Pharma") made an offer for the entire of the issued ... ("Elan") (the "Original Offer").  On 20 May ...
(Date:5/24/2013)... CITY, England and BOSTON ... leading GPCR drug discovery and development company, is pleased to announce ... as a Consultant to augment the Company,s business development capabilities in ... Mr Usui has more than 15 years of experience in business ... roles at Perlegen Sciences, Inc., Roche Pharma ( Japan ...
(Date:5/23/2013)... y PARÍS, 24 de mayo de 2013 ... un destacado desarrollador y fabricante de herramientas de ... diagnosis y tratamiento de la enfermedad vascular periférica ... ensayo ADVISE ( Ad enosine V asodilator ... valuation) II durante la sesión de ensayo clínico ...
Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
Cached News: